-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
With the global spread of the new crown epidemic in early 2020, the research and development work for COVID-19 has been quickly launched
No.
No.
Lenzilumab has entered clinical trials as early as 2009, when the drug was indicated for asthma and rheumatoid arthritis
- In 2015, a phase I clinical trial for chronic myelomonocytic leukemia (CMML) was launched;
- In 2019, it launched a phase I/II clinical trial in combination with Kite Pharma’s CD19 CAR-T product Yescarta for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL);
-
At the end of 2019, a phase II clinical trial for acute graft-versus-host disease (GvHD) is planned
No.
No.The widespread prevalence of the new crown epidemic in early 2020 and the characteristics of COVID-19 prone to trigger cytokine stormsyndromes (CSS) have prompted researchers to focus on the potential of GM-CSF in the treatment of COVID-19
The disease progression after COVID-19 infection is usually divided into three stages.
No.
No.Lenzilumab's Phase III randomized placebo controlled trial (NCT04351152) for the treatment of severe and critical COVID-19 pneumonia hospitalized patients was launched in May 2020
In March 2021, Humanigen announced the positive top-line results of Phase III clinical trials
The test results showed that Lenzilumab increased the survival rate (mITT population) without mechanical ventilation by 54% (HR: 1.
In addition, compared with placebo, subjects receiving corticosteroids and Remdesivir at the same time receiving Lenzilumab can effectively improve the survival rate without mechanical ventilation (HR: 1.
According to the company's plan, it will apply to the FDA for an emergency use authorization (EUA) of Lenzilumab for COVID-19 hospitalized patients in the near future
Note: The Sotrovimab neutralizing antibody jointly developed by Vir Biotechnology and GSK has recently been approved by EUA
